Pfizer is betting big on cancer drugs to turn business around after Covid decline – here’s what to know
The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.
Read More
Merck & Co Inc
Viking stock doubled Tuesday. Here’s where the next moves in the obesity space could come from
Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but it's coming. Source link
Read More
New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle
Breakthrough sickle cell treatments are available in the U.S., but their high cost is forcing insurers to get creative. Source
Read More
Fourth-quarter earnings are shaping up to be the best of 2023, but there’s a catch
Almost halfway into earnings season, profits are clearly coming in far better than anybody expected. Source link
Read More
Stocks making the biggest moves midday: Peloton, Honeywell, Norfolk Southern, Boot Barn and more
These are the stocks posting the largest moves in midday trading. Source link
Read More
5 things to know before the stock market opens Monday
Here are the most important news items that investors need to start their trading day. Source link
Read More
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen.
Read More
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer
Read More
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker
Read More